|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
EA201691376A1
(ru)
|
2014-02-04 |
2017-01-30 |
Пфайзер Инк. |
Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
|
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
CA2947605A1
(en)
|
2014-05-13 |
2015-11-19 |
Bioatla, Llc |
Conditionally active biological proteins
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
DK3221355T3
(da)
*
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
NZ733854A
(en)
|
2015-02-26 |
2022-07-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
CA3155409A1
(en)
*
|
2015-05-13 |
2016-11-17 |
Ablynx N.V. |
T cell recruiting polypeptides based on cd3 reactivity
|
|
CN107708741A
(zh)
*
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
|
US20180312561A1
(en)
*
|
2015-06-12 |
2018-11-01 |
Immungene, Inc. |
Focused interferon immunotherapy for treatment of cancer
|
|
PH12017501857B1
(en)
|
2015-06-16 |
2024-01-17 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
|
WO2017004149A1
(en)
*
|
2015-06-30 |
2017-01-05 |
Boehringer Ingelheim International Gmbh |
Multi-specific binding proteins
|
|
TWI746449B
(zh)
*
|
2015-07-20 |
2021-11-21 |
美商Ａｉ治療公司 |
使用阿吡莫德治療癌症之方法
|
|
KR20180086502A
(ko)
|
2015-12-16 |
2018-07-31 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항원-결합 단편
|
|
JP6942726B2
(ja)
*
|
2016-01-08 |
2021-09-29 |
ユークリセス ファーマシューティカルズ，インコーポレイテッド |
クロメン化合物および第２活性薬剤の併用薬
|
|
JP6949030B2
(ja)
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
JP7038353B2
(ja)
*
|
2016-04-13 |
2022-03-18 |
ヴィヴィア バイオテック，エス．エル |
エクスビボのｂｉｔｅ活性化ｔ細胞
|
|
WO2017184456A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Rima Mcleod |
Toxoplasma gondii vaccines and their use
|
|
WO2017189906A1
(en)
*
|
2016-04-27 |
2017-11-02 |
Mira Dx, Inc. |
Immune-based treatment of kras-variant cancer patients
|
|
JP7379795B2
(ja)
*
|
2016-04-27 |
2023-11-15 |
イミューノメディクス、インコーポレイテッド |
チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
|
|
CN109195992A
(zh)
*
|
2016-04-29 |
2019-01-11 |
本康生物制药（深圳）有限公司 |
多特异性结合偶联物、相关的药物组合物及应用
|
|
CN109416925A
(zh)
*
|
2016-05-05 |
2019-03-01 |
南托米克斯有限责任公司 |
检查点失效和使检查点失效的方法
|
|
SG11201810951RA
(en)
*
|
2016-06-10 |
2019-01-30 |
Io Therapeutics Inc |
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
CN105943510A
(zh)
*
|
2016-06-13 |
2016-09-21 |
佛山市腾瑞医药科技有限公司 |
一种艾代拉利司制剂及其应用
|
|
WO2018005973A1
(en)
|
2016-06-30 |
2018-01-04 |
Nant Holdings Ip, Llc |
Nant cancer vaccine
|
|
WO2018028449A1
(en)
*
|
2016-08-08 |
2018-02-15 |
Beigene, Ltd. |
Method for predicting efficacy of immune checkpoint inhibitors in cancer patients
|
|
BR112019005895A2
(pt)
|
2016-09-23 |
2019-06-11 |
Merus N.V. |
moléculas de ligação que modulam uma atividade biológica expressa por uma célula
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
EP3904880A1
(fr)
*
|
2016-09-30 |
2021-11-03 |
Centre national de la recherche scientifique |
Marqueurs membranaires
|
|
KR20190062515A
(ko)
|
2016-10-06 |
2019-06-05 |
화이자 인코포레이티드 |
암의 치료를 위한 아벨루맙의 투약 용법
|
|
JP6948685B2
(ja)
*
|
2016-11-04 |
2021-10-13 |
国立大学法人金沢大学 |
抗癌作用増強剤及び癌治療支援方法
|
|
JP2019533698A
(ja)
*
|
2016-11-04 |
2019-11-21 |
バクシム アクチェンゲゼルシャフト |
併用療法のためのｗｔ１標的指向性ｄｎａワクチン
|
|
US20200062836A1
(en)
*
|
2016-11-16 |
2020-02-27 |
Eli Lilly And Company |
THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
|
|
CN110573172A
(zh)
*
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
JP2020508323A
(ja)
*
|
2017-02-23 |
2020-03-19 |
ラクテン メディカル インコーポレイテッド |
光免疫療法のための治療用組成物および関連する方法
|
|
AU2018241781A1
(en)
*
|
2017-03-29 |
2019-07-18 |
Glycotope Gmbh |
Multispecific antibody constructs binding to MUC1 and CD3
|
|
KR20190136076A
(ko)
*
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
KR20200029544A
(ko)
|
2017-07-13 |
2020-03-18 |
아이오 테라퓨틱스, 인크. |
암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물
|
|
KR20200044889A
(ko)
|
2017-08-31 |
2020-04-29 |
아이오 테라퓨틱스, 인크. |
암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제
|
|
CN111491665B
(zh)
*
|
2017-09-26 |
2024-08-06 |
中外制药株式会社 |
药物组合物
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
CN109954131B
(zh)
*
|
2017-12-14 |
2023-05-02 |
深圳市中科艾深医药有限公司 |
一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用
|
|
CA3091181A1
(en)
*
|
2018-02-13 |
2019-08-22 |
Precision Biologics, Inc. |
Methods and compositions for targeting treg cells
|
|
KR102373502B1
(ko)
|
2018-05-14 |
2022-03-11 |
주식회사 금호에이치티 |
골수유래억제세포 관련 질환의 예방 및 치료 용도
|
|
EP3569617A1
(en)
*
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
|
EP3802595A1
(en)
*
|
2018-06-07 |
2021-04-14 |
OncoOne Research & Development GmbH |
Anti-oxmif/anti-cd3 antibody for cancer treatment
|
|
JP7541930B2
(ja)
*
|
2018-06-29 |
2024-08-29 |
ジーオー セラピューティクス，インコーポレイテッド |
抗グリコｍｕｃ１抗体およびその使用
|
|
CN113164445A
(zh)
*
|
2018-08-02 |
2021-07-23 |
得克萨斯系统大学评议会 |
Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病
|
|
CN112601526B
(zh)
*
|
2018-08-29 |
2025-10-03 |
凯莫森特里克斯股份有限公司 |
使用c-c趋化因子受体4(ccr4)拮抗剂和一种或多种检查点抑制剂的联合治疗
|
|
MA53812A
(fr)
*
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
EP3875470A4
(en)
*
|
2018-10-05 |
2023-01-18 |
RNAGENE Inc. |
CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION BY SPECIFIC BINDING TO A TARGET CELL, AND USE THEREOF
|
|
WO2020092736A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
JP7521163B2
(ja)
|
2018-12-19 |
2024-07-24 |
ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ |
抗ｃｅａｃａｍ６及びｔｉｍ３抗体の医薬組み合わせ
|
|
CN110846279B
(zh)
*
|
2018-12-27 |
2023-06-16 |
重庆医药高等专科学校附属第一医院 |
人套细胞淋巴瘤细胞株及其建立方法和应用
|
|
TWI858005B
(zh)
*
|
2019-01-21 |
2024-10-11 |
新加坡商新加坡保健服務私人有限公司 |
肝毒性之治療
|
|
CN113874399B
(zh)
*
|
2019-05-23 |
2025-07-11 |
维洛斯生物股份有限公司 |
抗ror1/抗cd3双特异性结合分子
|
|
KR20210021861A
(ko)
*
|
2019-08-19 |
2021-03-02 |
(주)제노팜 |
사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
|
|
EP4061487A4
(en)
*
|
2019-11-19 |
2023-12-20 |
Rootpath Genomics, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR
|
|
KR20220109436A
(ko)
|
2019-12-03 |
2022-08-04 |
에보텍 인터내셔널 게엠베하 |
인터페론-결합된 항원 결합 단백질 및 이의 용도
|
|
IL296755A
(en)
*
|
2020-03-27 |
2022-11-01 |
Univ Texas |
Monoclonal antibodies targeting hsp70 and their therapeutic uses
|
|
WO2021212037A1
(en)
*
|
2020-04-16 |
2021-10-21 |
Emory University |
Immune cell redirecting compositions and therapeutic uses thereof
|
|
CN111705013B
(zh)
*
|
2020-06-02 |
2021-12-07 |
华中农业大学 |
一种牛支原体Mbov_0570基因突变株及其应用
|
|
CA3182769A1
(en)
*
|
2020-06-15 |
2021-12-23 |
Andrew P. Mazar |
Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
|
|
CN111850002B
(zh)
*
|
2020-06-22 |
2022-04-19 |
华中农业大学 |
牛支原体分泌蛋白MbovP570的应用
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
WO2022046658A1
(en)
*
|
2020-08-24 |
2022-03-03 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
|
CN116472060A
(zh)
*
|
2020-09-02 |
2023-07-21 |
健玛保 |
抗体疗法
|
|
WO2022109038A1
(en)
*
|
2020-11-18 |
2022-05-27 |
University Of Florida Research Foundation, Inc. |
Materials and methods for sensitizing tumors to immune response
|
|
JP2022157223A
(ja)
*
|
2021-03-31 |
2022-10-14 |
国立大学法人神戸大学 |
抗ガン剤効果増強剤
|
|
JP7673255B2
(ja)
|
2021-06-11 |
2025-05-08 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
|
|
TWI910028B
(zh)
|
2021-06-11 |
2025-12-21 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗癌劑之組合
|
|
CN117883547A
(zh)
*
|
2021-07-30 |
2024-04-16 |
河北菲尼斯生物技术有限公司 |
Se-dr亲和肽在制备治疗风湿疾病的药物中的用途
|
|
CN118541392A
(zh)
*
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114209652B
(zh)
*
|
2021-12-29 |
2022-08-09 |
中山大学附属第一医院 |
一种微环境nk细胞免疫调控递送系统及其制备方法和应用
|
|
CN114300089B
(zh)
*
|
2022-01-04 |
2024-09-03 |
哈尔滨医科大学 |
一种中晚期结直肠癌治疗方案决策算法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CN119110809A
(zh)
|
2022-02-23 |
2024-12-10 |
Xencor股份有限公司 |
抗CD28 x抗PSMA抗体
|
|
US20240059786A1
(en)
*
|
2022-02-24 |
2024-02-22 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
US20250249115A1
(en)
|
2022-04-13 |
2025-08-07 |
Gilead Sciences, Inc. |
Combination therapy for treating tumor antigen expressing cancers
|
|
CN119173276A
(zh)
|
2022-04-13 |
2024-12-20 |
吉利德科学公司 |
用于治疗表达Trop-2的癌症的组合疗法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
TW202413405A
(zh)
*
|
2022-07-13 |
2024-04-01 |
美商翰森生物有限責任公司 |
抗體、其抗原結合片段及其藥物用途
|
|
WO2024097812A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Therapy for treating bladder cancer
|
|
CN115975026B
(zh)
*
|
2022-11-15 |
2024-06-25 |
青海大学 |
一种抗多房棘球蚴原头节的纳米抗体、重组菌及其应用
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025027090A1
(en)
*
|
2023-07-31 |
2025-02-06 |
Danmarks Tekniske Universitet |
Inhibitors of cell envelope proteinases from lactic acid bacteria
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
CN116874606B
(zh)
*
|
2023-09-08 |
2023-11-24 |
益科思特(北京)医药科技发展有限公司 |
一种靶向trop2和cd3的双特异性抗体及其制备方法与应用
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025184896A1
(zh)
*
|
2024-03-08 |
2025-09-12 |
四川大学华西医院 |
增强免疫检查点抑制剂抗肿瘤疗效的方法和药物及其应用
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN120518757B
(zh)
*
|
2025-07-23 |
2025-09-23 |
中国人民解放军军事科学院军事医学研究院 |
一种聚乙二醇化多价抗西尼罗病毒单链抗体
|
|
CN121293363B
(zh)
*
|
2025-12-09 |
2026-04-21 |
上海玄言生物科技有限公司 |
一种靶向cd14和cd3的双功能t细胞衔接器及其应用
|